Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.78 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.78 |
| ▸ | HDAC1 | Q13547 | 10/20 | 0.75 |
| ▸ | HDAC2 | Q92769 | 9/20 | 0.75 |
| ▸ | HDAC3 | O15379 | 8/20 | 0.75 |
| ▸ | HDAC4 | P56524 | 8/20 | 0.75 |
| ▸ | HDAC7 | Q8WUI4 | 8/20 | 0.75 |
| ▸ | HDAC10 | Q969S8 | 8/20 | 0.75 |
| ▸ | HDAC11 | Q96DB2 | 8/20 | 0.75 |
| ▸ | HDAC8 | Q9BY41 | 8/20 | 0.75 |
| ▸ | HDAC6 | Q9UBN7 | 8/20 | 0.75 |
| ▸ | HDAC9 | Q9UKV0 | 8/20 | 0.75 |
| ▸ | HDAC5 | Q9UQL6 | 8/20 | 0.75 |
| ▸ | MGAM | O43451 | 5/20 | 0.66 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | NQO1 | P15559 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23500758 | 0.92 | KMT2A (0.74) | MEN1KMT2AHDAC1HDAC2HDAC3 | |
| SCHEMBL23500588 | 0.90 | KMT2A (0.74) | MEN1KMT2AHDAC1HDAC2HDAC3 | |
| SCHEMBL12967988 | 0.89 | HDAC1 (0.78) | MEN1KMT2AHDAC1HDAC2HDAC3 | |
| SCHEMBL16489358 | 0.89 | HDAC1 (0.81) | MEN1KMT2AHDAC1HDAC2HDAC3 | |
| SCHEMBL2213731 | 0.88 | HDAC1 (0.70) | MEN1KMT2AHDAC1HDAC2HDAC3 | |
| SCHEMBL23500386 | 0.88 | MEN1 (0.83) | MEN1KMT2AHDAC1HDAC2HDAC3 | |
| Hydrochloric Acid SCHEMBL16470737 | 0.88 | HDAC1 (0.80) | MEN1KMT2AHDAC1HDAC2HDAC3 | |
| SCHEMBL18061333 | 0.88 | HDAC1 (0.80) | MEN1KMT2AHDAC1HDAC2HDAC3 | |
| SCHEMBL16489363 | 0.88 | MEN1 (1.00) | MEN1KMT2AMGAM | |
| SCHEMBL23500227 | 0.88 | KMT2A (0.71) | MEN1KMT2AHDAC1HDAC2HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021114864-A1 | β-CARBOLINE CYCLOKETENE DERIVATIVE BASED ON DUAL RESPONSE TO PH AND GSH, AND USE THEREOF | 南通大学 | 2021-06-17 | — | — | WO | disclosed |
| CN-110981870-A | β -carboline-cycloalkenone derivative based on dual responses of pH and GSH and application thereof | 南通大学 | 2020-04-10 | — | — | CN | disclosed |
| CN-105859713-B | A kind of harmel alkali oxazole oxazoline derivates and its preparation method and application | 华南农业大学 | 2017-08-08 | — | — | CN | disclosed |
| EP-2691394-B1 | COMPOUNDS FOR TREATMENT OF METABOLIC SYNDROME | SJT MOLECULAR RES S L (ES) | 2017-05-10 | — | — | EP | disclosed |
| US-20160340355-A1 | COMPOUNDS FOR TREATMENT OF METABOLIC SYNDROME | SJT MOLECULAR RES S L (ES) | 2016-11-24 | — | — | US | disclosed |
| US-20160340355-A1 | COMPOUNDS FOR TREATMENT OF METABOLIC SYNDROME | SJT MOLECULAR RES S L (ES) | 2016-11-24 | — | — | US | disclosed |
| US-9440966-B2 | Compounds for treatment of metabolic syndrome | SJT MOLECULAR RESEARCH, S.L. (ES) | 2016-09-13 | — | — | US | disclosed |
| US-9440966-B2 | Compounds for treatment of metabolic syndrome | SJT MOLECULAR RESEARCH, S.L. (ES) | 2016-09-13 | — | — | US | disclosed |
| US-20150051204-A1 | COMPOUNDS FOR TREATMENT OF METABOLIC SYNDROME | SJT MOLECULAR RESEARCH, S.L. (ES) | 2015-02-19 | — | — | US | disclosed |
| US-20150051204-A1 | COMPOUNDS FOR TREATMENT OF METABOLIC SYNDROME | SJT MOLECULAR RESEARCH, S.L. (ES) | 2015-02-19 | — | — | US | disclosed |
| WO-2012130912-A1 | COMPOUNDS FOR TREATMENT OF METABOLIC SYNDROME | SJT MOLECULAR RESEARCH, S.L. (ES) | 2012-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160340355-A1 | COMPOUNDS FOR TREATMENT OF METABOLIC SYNDROME | GPR119, GOT2, PC | MEN1 1156/4885KMT2A 2006/4885HDAC1 796/4885 |
| US-20150051204-A1 | COMPOUNDS FOR TREATMENT OF METABOLIC SYNDROME | GPR119, GOT2, PC | MEN1 1156/4885KMT2A 2006/4885HDAC1 796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.